Puma Biotechnology (PBYI) Total Debt (2011 - 2026)

Puma Biotechnology has reported Total Debt for 9 years, with the latest figure at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 79.84% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (down 79.84% YoY), and the FY2025 full-year result was $22.5 million, down 66.41% from the prior year.
• Total Debt for Q1 2026 stood at $11.3 million, down from $22.5 million in the prior quarter.
• The five-year high for Total Debt was $100.0 million in Q1 2024, with the low at $11.3 million in Q1 2026.
• Historically, Total Debt has averaged $75.9 million across 5 years, with a median of $97.4 million in 2022.
• Annual changes were most pronounced in 2024 — Total Debt grew 1.42% — and 2026, when it plunged 79.84%.
• Puma Biotechnology's Total Debt stood at $98.3 million in 2022, then rose by 1.37% to $99.7 million in 2023, then slumped by 32.72% to $67.0 million in 2024, then sank by 66.41% to $22.5 million in 2025, then tumbled by 49.9% to $11.3 million in 2026.
• The last three Total Debt figures came in at $11.3 million (Q1 2026), $22.5 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.